Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - OncoMed Pharmaceuticals Inc | omed-ex312_62.htm |
| EX-31.1 - EX-31.1 - OncoMed Pharmaceuticals Inc | omed-ex311_10.htm |
| EX-23.1 - EX-23.1 - OncoMed Pharmaceuticals Inc | omed-ex231_7.htm |
| EX-10.13 - EX-10.13 - OncoMed Pharmaceuticals Inc | omed-ex1013_142.htm |
| EX-10.7(D) - EX-10.7(D) - OncoMed Pharmaceuticals Inc | omed-ex107d_141.htm |
| 10-K - 10-K - OncoMed Pharmaceuticals Inc | omed-10k_20171231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of OncoMed Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission (the “Report”), John Lewicki, President of the Company, and Sunil Patel, Executive Vice President and Chief Financial Officer of the Company, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
• |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
• |
The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 8, 2018
|
|
|
/s/ John Lewicki |
|
John Lewicki, Ph.D. |
|
President |
|
(principal executive officer) |
|
|
|
/s/ Sunil Patel |
|
Sunil Patel |
|
Executive Vice President and Chief Financial Officer |
|
(principal financial and accounting officer) |
This certification is being furnished to accompany the Report pursuant to 18 U.S.C. § 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.